Diana Do, MD, professor of ophthalmology and vice chair of clinical affairs at the Byers Eye Institute at Stanford University, spoke with our team about the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular edema at the 2023 ASRS meeting in Seattle, Washington.
This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.
In a presentation at the ASRS 41st Annual Meeting in Seattle, Diana Do, MD, said the PHOTON study demonstrated the potential aflibercept 8 mg could have in reducing the treatment burden for patients.
RGX-314, an investigational formulation being developed in collaboration with AbbVie, may be a potential one-time treatment for nAMD, diabetic retinopathy, and other chronic retinal conditions.
According to Clearside Biomedical, a pair of presentations at the ASRS annual meeting in Seattle highlight CLS-AX as a potential treatment option for wet AMD treatment with a new mechanism of action and the possibility for longer duration of effect than current therapies.
Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.
At the 2023 ASRS meeting in Seattle, Washington, Carl Danzig, MD, caught up with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy.
Aaron Lee, MD, shared how research and new techniques are expanding the options for deep learning in ophthalmology. He spoke with our team at the 2023 ASRS meeting in Seattle, Washington to share more about this research.
The company announced at the ASRS annual meeting in Seattle the phase 2 Dose Expansion (N=50) initial interim efficacy and safety data presentation expected at medical conference in H1 2024.
Jennifer I. Lim, MD, FARVO, FASRS shared insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis" with our team.
Lim and colleagues conducted a retrospective study to establish the normalized NBFI using OCTA and test if that index is sufficiently sensitive for detecting early DR.
The American Society of Retina Specialists is hosting its annual meeting this year in Seattle, Washington. Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.
Detrimental effects of IVB may not be recognized at an early age, which underscores the importance of following these children over time.
APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy.
The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.
Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists 2023 annual meeting in Seattle, Washington, including a late-breaking presentation on Vabysmo’s effect on epiretinal membrane (ERM) formation in DME compared to aflibercept.
The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.
The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on July 31, 2023 in Seattle, Washington.
Apellis has announced that seven abstracts will be presented at the American Society of Retina Specialists Annual Scientific Meeting including safety and efficacy data for the company’s pegcetacoplan injection for geographic atrophy (GA).
The 2023 41st annual meeting of the American Society of Retina Specialists (ASRS) will run from Thursday, July 27 to Tuesday, August 1 in Seattle, a city filled with sightseeing, museums, and great food to explore.
ASRS is an international, state-or-the-art event offering something for everyone: scientific papers, posters, panel discussions on controversial issues and techniques, award lectures, a Retina Case Conference, the 25th Annual Film Festival, international symposia, and subspecialty review courses.
Antimicrobial resistance is resistance to multiple classes of antibiotics, which makes it extremely challenging to treat infections caused by such organisms.
Artificial intelligence (AI) is going to be highly instrumental in patient care in all medical specialties and will be highly relevant in eye care.
Ala Moshiri, MD, PhD, provides an overview of current treatment options for diabetic macular edema.
Jorge L. Alió, MD, PhD, FEBOphth, shared his pearls situations in which a patient presents with a cataract and corneal opacity at the European Society of Ophthalmology Conference, Prague.
Paracentral acute middle maculopathy can develop after excessive intake of caffeine and alcohol according to Obadah Moushmoush, MD.
Omnigen® may be an alternative treatment option for patients with a persistent corneal epithelial defect. The product provides a convenient and effective treatment that can be administered in an outpatient setting.
The 12-month data demonstrated maintenance of controlled wet AMD subjects comparable to aflibercept injections every eight weeks with a single administration of OTX-TKI.
